Although IL-37 has shown protective roles in RA, its pharmacokinetics in vivo remain poorly characterised, and it is unclear whether endogenous IL-37 or IL-38 can be sufficiently upregulated in response to immunogenic triggers. The gene discussed is IL37; the disease is rheumatoid arthritis.